Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial

M Schell; I Pflüger; G Brugnara; F Isensee; U Neuberger; M Foltyn; T Kessler; F Sahm; A Wick; M Nowosielski; S Heiland; M Weller; M Platten; KH Maier-Hein; A von Deimling; Martin van den Bent; T Gorlia; W Wick; M Bendszus; P Kickingereder

doi:10.1093/neuonc/noaa120

Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial

M Schell, I Pflüger, G Brugnara, F Isensee, U Neuberger, M Foltyn, T Kessler, F Sahm, A Wick, M Nowosielski, S Heiland, M Weller, M Platten, KH Maier-Hein, A von Deimling, Martin van den Bent, T Gorlia, W Wick, M Bendszus, P Kickingereder

Neurology

Research output: Contribution to journal › Article › Academic › peer-review

5 Citations (Scopus)

Original language	English
Pages (from-to)	1667-1676
Number of pages	10
Journal	Neuro-Oncology
Volume	22
Issue number	11
DOIs	https://doi.org/10.1093/neuonc/noaa120
Publication status	Published - 2020

Access to Document

10.1093/neuonc/noaa120

http://hdl.handle.net/1765/133829

Cite this

Schell, M., Pflüger, I., Brugnara, G., Isensee, F., Neuberger, U., Foltyn, M., Kessler, T., Sahm, F., Wick, A., Nowosielski, M., Heiland, S., Weller, M., Platten, M., Maier-Hein, KH., von Deimling, A., van den Bent, M., Gorlia, T., Wick, W., Bendszus, M., & Kickingereder, P. (2020). Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial. Neuro-Oncology, 22(11), 1667-1676. https://doi.org/10.1093/neuonc/noaa120

@article{11a9d757bf8e476083da78f17ac93c2e,

title = "Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial",

author = "M Schell and I Pfl{\"u}ger and G Brugnara and F Isensee and U Neuberger and M Foltyn and T Kessler and F Sahm and A Wick and M Nowosielski and S Heiland and M Weller and M Platten and KH Maier-Hein and {von Deimling}, A and {van den Bent}, Martin and T Gorlia and W Wick and M Bendszus and P Kickingereder",

year = "2020",

doi = "10.1093/neuonc/noaa120",

language = "English",

volume = "22",

pages = "1667--1676",

journal = "Neuro-Oncology",

issn = "1522-8517",

publisher = "Oxford University Press",

number = "11",

}

Schell, M, Pflüger, I, Brugnara, G, Isensee, F, Neuberger, U, Foltyn, M, Kessler, T, Sahm, F, Wick, A, Nowosielski, M, Heiland, S, Weller, M, Platten, M, Maier-Hein, KH, von Deimling, A, van den Bent, M, Gorlia, T, Wick, W, Bendszus, M & Kickingereder, P 2020, 'Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial', Neuro-Oncology, vol. 22, no. 11, pp. 1667-1676. https://doi.org/10.1093/neuonc/noaa120

TY - JOUR

T1 - Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial

AU - Schell, M

AU - Pflüger, I

AU - Brugnara, G

AU - Isensee, F

AU - Neuberger, U

AU - Foltyn, M

AU - Kessler, T

AU - Sahm, F

AU - Wick, A

AU - Nowosielski, M

AU - Heiland, S

AU - Weller, M

AU - Platten, M

AU - Maier-Hein, KH

AU - von Deimling, A

AU - van den Bent, Martin

AU - Gorlia, T

AU - Wick, W

AU - Bendszus, M

AU - Kickingereder, P

PY - 2020

Y1 - 2020

U2 - 10.1093/neuonc/noaa120

DO - 10.1093/neuonc/noaa120

M3 - Article

VL - 22

SP - 1667

EP - 1676

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 11

ER -